

Name Of The Company PHARMAIDS PHARMACEUTICALS LIMITED

STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 30th JUNE,2016				
Particulars	QUARTER ENDED			YEAR ENDED
	30.06.2016	31.03.2016	30.06.2015	31.03.2016
	Unaudited	Audited	Unaudited	Audited
Income				
Revenue from Operations	34.20	26.55	57.49	168.45
Other Income	0.04	0.00	0.00	4.57
Total Income	34.24	26.55	57.49	173.02
Expenses				
Cost of Material Consumed	3.19	0.00	5.10	0.00
Purchase of Stock in Trade	10.23	25.66	21.61	114.51
Changes in Inventory of Finished Goods, Work in Progress and Stock in Trade	7.95	5.24	5.57	0.89
Employee benefit expenses	5.98	3.70	5.18	20.30
Finance Cost	1.37	1.03	0.03	2.87
Depreciation and amortisation expense	1.96	2.91	2.42	10.37
Other expenses	5.41	8.01	12.43	67.29
Total expenses	36.09	46.55	52.34	216.23
Profit/ (loss) before exceptional items and tax	(1.85)	(20.00)	5.15	(43.21)
Exceptional items	0.04	0.00	0.00	0.00
Profit/ (loss) before tax	(1.81)	(20.00)	5.15	(43.21)
Tax expenses	0.00	0.00	0.00	0.00
Profit/ (loss) for the period from continuing operations	0.00	0.00	0.00	0.00
Profit/ (loss) from discontinued operations	0.00	0.00	0.00	0.00
Tax expense of discontinued operations	0.00	0.00	0.00	3.45
Profit/ (loss) from discounting operations (after tax)	0.00	0.00	0.00	0.00
Profit/ (loss) for the period	(1.81)	(20.00)	5.15	(39.76)
Other comprehensive income	0.00	0.00	0.00	0.00
Total comprehensive income for the period	0.00	0.00	0.00	0.00
(Profit/ loss + other comprehensive income)	0.00	0.00	0.00	0.00
Earnings per equity share (for continuing operations)				
a) Basic	(0.05)	(0.59)	(0.48)	(1.17)
b) Diluted	(0.05)	(0.59)	(0.48)	(1.17)
Earnings per equity share (for discontinued operations)				
a) Basic	0.00	0.00	0.00	0.00
b) Diluted	0.00	0.00	0.00	0.00
Earnings per equity share (for discontinued & continuing operations)				
a) Basic	(0.05)	(0.59)	(0.48)	(1.17)
b) Diluted	(0.05)	(0.59)	(0.48)	(1.17)

NOTES: 1. These results were approved at the meeting of the Board of Directors held on August 13,2016. 2. The Company operates in a single segment 3. As required under Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation,2015, the Limited Review by the Statutory Auditors has been completed and the Unmodified Report forwarded to BSE Ltd. The said Report does not have any impact on the above results and Notes which needs explanation. 4. Figures for the previous periods have been regrouped wherever necessary, to correspond with the current period.

